MENU
+Compare
IMAB
Stock ticker: NASDAQ
AS OF
Jun 27 closing price
Price
$2.57
Change
+$0.55 (+27.23%)
Capitalization
209.05M

IMAB I-MAB Forecast, Technical & Fundamental Analysis

I-MAB is a clinical-stage biotech company... Show more

IMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for IMAB with price predictions
Jun 27, 2025

IMAB's RSI Indicator recovers from overbought zone

The 10-day RSI Oscillator for IMAB moved out of overbought territory on June 26, 2025. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 18 instances where the indicator moved out of the overbought zone. In of the 18 cases the stock moved lower in the days that followed. This puts the odds of a move down at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on June 26, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on IMAB as a result. In of 101 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for IMAB turned negative on June 23, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMAB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 68 cases where IMAB's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The 50-day moving average for IMAB moved above the 200-day moving average on June 10, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

IMAB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 77 cases where IMAB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. IMAB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.058) is normal, around the industry mean (16.366). P/E Ratio (0.000) is within average values for comparable stocks, (58.189). IMAB's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.309). Dividend Yield (0.000) settles around the average of (0.041) among similar stocks. P/S Ratio (16.978) is also within normal values, averaging (252.247).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMAB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
IMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

IMAB is expected to report earnings to rise 539.50% to -12 cents per share on November 29

I-MAB IMAB Stock Earnings Reports
Q3'23
Est.
$-0.13
Q1'25
Beat
by $0.09
Q4'24
Est.
$-0.06
Q3'24
Missed
by $0.04
Q2'24
Beat
by $0.22
The last earnings report on May 15 showed earnings per share of -1 cents, beating the estimate of -10 cents. With 2.59M shares outstanding, the current market capitalization sits at 209.05M.
A.I. Advisor
published General Information

General Information

a clinical stage biopharmaceutical company, which engages in developing and commercialization of differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders.

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
555 West Haiyang Road
Phone
+86 2160578000
Employees
318
Web
https://www.i-mabbiopharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AVNBF26.051.85
+7.64%
AVON TECHNOLOGIES PLC
LUCMF1.020.01
+1.29%
LUCA MINING CORP.
SSUMF25.100.03
+0.10%
Sumitomo Corp.
FPRUY36.31N/A
N/A
Fraport AG
LVXFF0.26N/A
N/A
Leviathan Gold Ltd.

IMAB and Stocks

Correlation & Price change

A.I.dvisor tells us that IMAB and RPRX have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that IMAB and RPRX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IMAB
1D Price
Change %
IMAB100%
+27.23%
RPRX - IMAB
31%
Poorly correlated
+1.76%
IKNA - IMAB
30%
Poorly correlated
+1.49%
TPST - IMAB
27%
Poorly correlated
-2.68%
LGND - IMAB
27%
Poorly correlated
-1.33%
KPRX - IMAB
27%
Poorly correlated
-3.63%
More